Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 10/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.50 |
| ▸ | SCN1A | P35498 | 1/20 | 0.45 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20190617 | 0.91 | SCN5A (0.61) | SCN5ACYP1A2SCN1ASCN2AKDM4E | |
| SCHEMBL26539447 | 0.90 | SCN5A (0.50) | SCN5ACYP1A2SCN1ASCN2AKDM4E | |
| SCHEMBL26539455 | 0.86 | SCN5A (0.49) | SCN5ACYP1A2SCN1ASCN2AKDM4E | |
| SCHEMBL26539353 | 0.86 | SCN5A (0.49) | SCN5ACYP1A2SCN1ASCN2AKDM4E | |
| SCHEMBL26539441 | 0.83 | SCN5A (0.46) | SCN5ACYP1A2SCN1ASCN2AKDM4E | |
| SCHEMBL26539438 | 0.82 | SCN5A (0.46) | SCN5ACYP1A2SCN1ASCN2A | |
| SCHEMBL26539323 | 0.82 | CYP1A2 (0.49) | SCN5ACYP1A2SCN1ASCN2ACACNA2D1 | |
| SCHEMBL20203835 | 0.80 | ADORA3 (0.45) | SCN5ACYP1A2SCN1ASCN2AMAPT | |
| SCHEMBL20203952 | 0.80 | SCN5A (0.62) | SCN5ACYP1A2SCN1ASCN2A | |
| SCHEMBL26308617 | 0.77 | CYP1A2 (0.39) | SCN5ACYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | SCN5A 8/4885CYP1A2 1988/4885SCN1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.